Evaluating Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography /Computed Tomography With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Change from baseline in summed standardized uptake value (SUVmax) of lesion after 2 or 4 cycles
研究概览
简要总结
The purpose of this study is to evaluate whether a semi-quantitative interpretation using the liver SUVmax as reference can better interpret 18F-FDG PET/CT and predict disease progression during chemotherapy or survival in PTCL.
详细描述
In this study investigators develope a semi-quantitative interpretation using the liver SUVmax as reference to interpret 18F-FDG PET/CT. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold or new 18F-FDG avid lesions. Investigators compare the prognostic accuracy of the liver SUVmax-based criteria with the 5-PS criteria and ΔSUVmax interpretation with respect to predicting disease progression during chemotherapy or survival in PTCL. Furthermore,investigators improve the prognostic ability of interim PET/CT by comparing the results to the clinical prognostic factors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •newly diagnosed PTCL
- •treated using an anthracycline-containing regimen
- •minimal follow-up at 6 months after the completion of first-line treatment
- •complete medical history and clinicopathological data
排除标准
- •secondary malignant disease
- •serious infection or inflammation (e.g., HIV)
- •primary central nervous system lymphoma
- •hepatic or renal dysfunction.
研究组 & 干预措施
PTCL patients with 18F-FDG PET/CT
18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
干预措施: 18F-FDG PET/CT (Device)
结局指标
主要结局
Change from baseline in summed standardized uptake value (SUVmax) of lesion after 2 or 4 cycles
时间窗: baseline(diagnosed by pathology and before chemotherapy) and 2 or 4 cycles after starting chemotherapy (each cycle 21days)
次要结局
- 3 year progression-free survival(up to 3 years after initial diagnosis)
研究者
Xuejuan Wang,MD
Principal Investigator
Peking University Cancer Hospital & Institute